Aurobindo Pharma Ltd vs Lasa Supergenerics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 14, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1509 as of 14 May 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of Lasa Supergenerics Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of Lasa Supergenerics Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Aurobindo Pharma Ltd for the Dec '25 is ₹ 8833 crore as compare to the Sep '25 revenue of ₹ 8407 crore. This represent the growth of 5.07% The revenue of Lasa Supergenerics Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Aurobindo Pharma Ltd for the Dec '25 is ₹ 1896 crore as compare to the Sep '25 ebitda of ₹ 1800 crore. This represent the growth of 5.31% The ebitda of Lasa Supergenerics Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 909.8 crore over 7 quarters. This represents a CAGR of -0.53% The net profit of Lasa Supergenerics Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

FAQs for the comparison of Aurobindo Pharma Ltd and Lasa Supergenerics Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Lasa Supergenerics Ltd?

Market cap of Aurobindo Pharma Ltd is 87,680 Cr while Market cap of Lasa Supergenerics Ltd is 39 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Lasa Supergenerics Ltd?

The stock performance of Aurobindo Pharma Ltd and Lasa Supergenerics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Lasa Supergenerics Ltd?

As of May 14, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1509.65. On the other hand, Lasa Supergenerics Ltd stock price is INR ₹7.87.

How do dividend payouts of Aurobindo Pharma Ltd and Lasa Supergenerics Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Lasa Supergenerics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.